Akums Drugs & Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,056Cr
- +11.9% YoY
- +4.6% QoQ
- Net profit
- ₹150Cr
- Turned profitable YoY
- +127.3% QoQ
- Margin
- 9%
- +8.7 pp YoY
- −3 pp QoQ
Guidance rank: #25 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Akums Drugs & Pharmaceuticals Ltd Q4 FY25 key numbers
- Revenue
- Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth.
As stated in Akums Drugs & Pharmaceuticals Ltd's Q4 FY25 earnings call transcript · published 6 Aug 2026. Reported figures, not investment advice.
The short version
Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. Revenue Growth: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).
From Akums Drugs & Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth.
- Domestic Formulations: Targeting double-digit top-line growth, higher than overall Indian pharma market growth of around 8-9%.
- CDMO Business: Expecting at least 20% year-on-year growth in current export and CDMO business. Volume growth targeted in single high digits (~9% QoQ currently), with revenues dependent on volatile API prices.
- Export Business: Base branded export business expected to grow at high double digits (~20%+) over next 2-3 years.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex.
- Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms.
- EUR 20 million (approx. INR 160+ crores) planned for plant upgrades and dossier development to meet European GMP standards for a large 6-year European contract.
- New product facility being set up at Baddi 1 (A 11) for serving European markets.
- Strategy includes adding capacity with foresight of 24 months due to plant validation timelines.
- Capacity expansions are spread across dosage forms, including injectables, oral solids, oral liquids, oncologics, and steroids.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Akums Drugs & Pharmaceuticals has a significant contract in Europe valued at EUR100 million (~INR950 crores part payment received on April 9, 2025).
- This contract is structured as a 6-year deal, expected to generate roughly INR300-350 crores in annual revenue.
- The European contract marks entry into about 20 countries.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Akums Drugs & Pharmaceuticals Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,056 | 944 | +11.9% | 1,010 | +4.6% |
| Operating profit (EBITDA) | 94 | 3 | +3033.3% | 121 | -22.3% |
| Operating margin | 9% | 0.3% | +8.7 pp | 12% | -3 pp |
| Profit before tax | 75 | -33 | — | 91 | -17.6% |
| Net profit (PAT) | 150 | -39 | — | 66 | +127.3% |
| EPS (₹) | 9.38 | -2.89 | — | 4.14 | +126.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q4 FY25 results?
Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. Revenue Growth: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex. - Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms. - EUR 20 million (approx.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
